P/E ratio for ANI Pharmaceuticals (ANIP)
P/E ratio as of March 2025 (TTM): -143
According to ANI Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -143.436. At the end of 2022 the company had a P/E ratio of -13.2.
P/E ratio history for ANI Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -13.2 | -6.66% |
| 2021 | -14.2 | -8.21% |
| 2020 | -15.4 | -112.52% |
| 2019 | 123 | 261.64% |
| 2018 | 34.1 | -104.76% |
| 2017 | -716 | -501.65% |
| 2016 | 178 | 429.39% |
| 2015 | 33.7 | 52.9% |
| 2014 | 22.0 | -766.96% |
| 2013 | -3.30 | 246.37% |
| 2012 | -0.9535 | 1.07% |
| 2011 | -0.9434 | -59.06% |
| 2010 | -2.30 | 122.5% |
| 2009 | -1.04 | -34.75% |
| 2008 | -1.59 | -87.4% |
| 2007 | -12.6 | -154.58% |
| 2006 | 23.1 | -416.21% |
| 2005 | -7.30 | -6.75% |
| 2004 | -7.83 | 4% |
| 2003 | -7.53 | 23.58% |
| 2002 | -6.09 | -69.19% |
| 2001 | -19.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -88.3 | -38.44% | 🇮🇪 Ireland |
 | -1.14 | -99.20% | 🇺🇸 USA |
 | -7.54 | -94.75% | 🇮🇱 Israel |
 | 13.5 | -109.40% | 🇺🇸 USA |
 | -0.0271 | -99.98% | 🇺🇸 USA |
 | -8.22 | -94.27% | 🇺🇸 USA |
 | 135 | -193.86% | 🇺🇸 USA |
 | 30.1 | -120.99% | 🇨🇭 Switzerland |
 | 56.9 | -139.68% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.